Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model
Sign Up to like & getrecommendations! Published in 2022 at "Age and Ageing"
DOI: 10.1093/ageing/afac115
Abstract: Abstract Introduction residents of long-term care facilities (LTCFs) are at high risk of adverse outcomes from SARS-CoV-2. We aimed to estimate the vaccine effectiveness (VE) of one and two doses of BNT162b2 and ChAdOx-1 against… read more here.
Keywords: long term; time; chadox; bnt162b2 chadox ... See more keywords
Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
Sign Up to like & getrecommendations! Published in 2021 at "BMJ Global Health"
DOI: 10.1136/bmjgh-2021-007321
Abstract: Objectives The Oxford–AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate… read more here.
Keywords: oxford astrazeneca; chadox; astrazeneca covid; funding ... See more keywords